However, due to the clonal evolution, intratumoral and interpatient heterogeneity of HCC [4,5], like AFP, the diagnostic validity and clinical applicability of all these serological biomarkers remain debatable, especially considering their sub-optimal diagnostic specificity and sensitivity for early detection of HCC [6,7]. This evidence concerns the gene AFP and hepatocellular carcinoma.